|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
43.08(B) |
Last
Volume: |
4,690,332 |
Avg
Vol: |
1,930,532 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
71,005 |
274,979 |
309,595 |
581,627 |
Total Sell Value |
$9,585,020 |
$36,298,507 |
$40,264,880 |
$70,726,419 |
Total People Sold |
8 |
10 |
14 |
16 |
Total Sell Transactions |
13 |
27 |
50 |
85 |
End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Balo Andrew K |
EVP, Clinical and Regulatory |
|
2017-01-10 |
4 |
AS |
$62.86 |
$201,152 |
D/D |
(3,200) |
106,345 |
|
- |
|
Balo Andrew K |
EVP, Clinical and Regulatory |
|
2017-01-10 |
4 |
OE |
$9.80 |
$31,360 |
D/D |
3,200 |
109,545 |
|
- |
|
Gregg Terrance H |
Executive Chairman |
|
2017-01-09 |
4 |
D |
$63.50 |
$95,949 |
D/D |
(1,511) |
441,266 |
|
- |
|
Lister John |
General Manager, EMEA |
|
2017-01-09 |
4 |
AS |
$63.02 |
$189,046 |
D/D |
(3,000) |
70,598 |
|
- |
|
Lister John |
General Manager, EMEA |
|
2017-01-09 |
4 |
OE |
$8.85 |
$26,550 |
D/D |
3,000 |
73,598 |
|
- |
|
Valdes Jorge A |
CTO |
|
2017-01-09 |
4 |
AS |
$62.83 |
$686,905 |
D/D |
(10,900) |
72,334 |
|
- |
|
Valdes Jorge A |
CTO |
|
2017-01-09 |
4 |
OE |
$3.19 |
$80,291 |
D/D |
10,900 |
74,917 |
|
- |
|
Doubleday Richard |
EVP, Chief Commercial Officer |
|
2016-12-23 |
4 |
AS |
$62.17 |
$197,831 |
I/I |
(3,182) |
19,097 |
|
- |
|
Gregg Terrance H |
Executive Chairman |
|
2016-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
55,882 |
|
- |
|
Sayer Kevin R |
President & CEO |
|
2016-12-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
299,391 |
|
- |
|
Roper Jess |
SVP, CFO |
|
2016-12-14 |
4 |
AS |
$64.14 |
$156,619 |
I/I |
(2,442) |
15,797 |
|
- |
|
Murphy Patrick Michael |
VP, Legal Aff & Chf Compl Ofcr |
|
2016-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,128 |
|
- |
|
Valdes Jorge A |
CTO |
|
2016-12-09 |
4 |
AS |
$64.81 |
$648,079 |
D/D |
(10,000) |
72,334 |
|
- |
|
Valdes Jorge A |
CTO |
|
2016-12-09 |
4 |
OE |
$7.25 |
$76,043 |
D/D |
10,000 |
76,259 |
|
- |
|
Gregg Terrance H |
Executive Chairman |
|
2016-12-09 |
4 |
D |
$64.46 |
$139,685 |
D/D |
(2,167) |
442,777 |
|
- |
|
Doubleday Richard |
EVP, Chief Commercial Officer |
|
2016-11-23 |
4 |
AS |
$70.19 |
$223,350 |
I/I |
(3,182) |
22,279 |
|
- |
|
Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
|
2016-11-23 |
4 |
AS |
$70.32 |
$724,260 |
D/D |
(10,300) |
110,409 |
|
- |
|
Lister John |
General Manager, EMEA |
|
2016-11-09 |
4 |
AS |
$62.50 |
$213,563 |
D/D |
(3,417) |
70,598 |
|
- |
|
Gregg Terrance H |
Executive Chairman |
|
2016-11-09 |
4 |
D |
$62.17 |
$135,042 |
D/D |
(2,172) |
444,944 |
|
- |
|
Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
|
2016-10-24 |
4 |
AS |
$81.95 |
$844,065 |
D/D |
(10,300) |
120,709 |
|
- |
|
Roper Jess |
SVP, CFO |
|
2016-10-24 |
4 |
AS |
$80.75 |
$199,544 |
D/D |
(2,471) |
74,215 |
|
- |
|
Doubleday Richard |
EVP, Chief Commercial Officer |
|
2016-10-24 |
4 |
AS |
$81.12 |
$258,110 |
I/I |
(3,182) |
25,461 |
|
- |
|
Balo Andrew K |
EVP, Clinical and Regulatory |
|
2016-10-19 |
4 |
AS |
$82.31 |
$411,303 |
D/D |
(4,997) |
106,345 |
|
- |
|
Sayer Kevin R |
President & CEO |
|
2016-10-14 |
4 |
AS |
$81.87 |
$573,101 |
D/D |
(7,000) |
299,891 |
|
- |
|
Lister John |
General Manager, EMEA |
|
2016-10-10 |
4 |
AS |
$84.41 |
$300,508 |
D/D |
(3,560) |
74,015 |
|
- |
|
2309 Records found
|
|
Page 39 of 93 |
|
|